Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) Director Sells 318 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Director Sangeeta Bhatia sold 318 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $423.73, for a total value of $134,746.14. Following the sale, the director owned 4,924 shares in the company, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vertex Pharmaceuticals Price Performance

Shares of VRTX traded down $5.49 on Tuesday, reaching $424.36. 1,905,665 shares of the stock traded hands, compared to its average volume of 1,400,388. The firm has a market cap of $107.94 billion, a price-to-earnings ratio of 27.68, a P/E/G ratio of 1.84 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $507.92. The stock’s 50-day moving average price is $453.82 and its 200-day moving average price is $449.48.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. The business had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.Vertex Pharmaceuticals’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the business posted $4.06 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.81 earnings per share for the current fiscal year.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 financials showed underlying strength — non?GAAP EPS beat consensus and product revenue grew ~8% year?over?year, driven by cystic fibrosis and new products; management reiterated FY2026 revenue guidance around $13.0–13.1B. Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Positive Sentiment: Management highlighted pipeline progress and contribution from new disease?area products (CASGEVY, KASJEVY/GERNAVICS), which management says accounted for a meaningful share of recent product growth — a potential multi?year revenue driver beyond CF. VRTX’s Q1 Earnings Beat Estimates, New Products Aid Sales Growth
• Neutral Sentiment: The full earnings call transcript, slide deck and summaries are available for investors to review management’s details on commercial execution and R&D timelines (useful for modeling but not new info). Vertex (VRTX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Concise call summaries (Moby, TipRanks) reiterate execution themes and R&D updates; these help refine timing assumptions but do not alter guidance. Vertex Q1 2026 Earnings Call Summary
• Negative Sentiment: Several analysts trimmed price targets and updated forecasts after the report, citing mixed top?line/EPS read and cautious near?term expectations — analyst downgrades/target cuts are pressuring sentiment. These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
• Negative Sentiment: Some data providers reported revenue/EPS slightly below certain consensus figures and highlighted extensive insider selling and large institutional rebalances — factors that can amplify near?term downside even if fundamentals remain intact. Vertex (VRTX) Stock Falls on Q1 2026 Earnings

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on VRTX shares. Jefferies Financial Group initiated coverage on Vertex Pharmaceuticals in a research report on Tuesday, March 10th. They set a “buy” rating and a $580.00 price objective on the stock. HC Wainwright upped their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Evercore upped their price target on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Scotiabank upped their price target on Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Finally, Truist Financial upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $554.83.

Institutional Trading of Vertex Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Beaumont Financial Advisors LLC grew its position in Vertex Pharmaceuticals by 4.9% in the first quarter. Beaumont Financial Advisors LLC now owns 510 shares of the pharmaceutical company’s stock valued at $228,000 after acquiring an additional 24 shares during the period. Midwest Professional Planners LTD. boosted its stake in Vertex Pharmaceuticals by 0.7% in the first quarter. Midwest Professional Planners LTD. now owns 3,549 shares of the pharmaceutical company’s stock worth $1,585,000 after purchasing an additional 25 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Vertex Pharmaceuticals by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 1,586,427 shares of the pharmaceutical company’s stock worth $708,403,000 after purchasing an additional 58,841 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Vertex Pharmaceuticals by 23.7% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,014 shares of the pharmaceutical company’s stock worth $1,346,000 after purchasing an additional 578 shares in the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH boosted its stake in Vertex Pharmaceuticals by 49.6% in the first quarter. MASTERINVEST Kapitalanlage GmbH now owns 8,293 shares of the pharmaceutical company’s stock worth $3,703,000 after purchasing an additional 2,749 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.